Terms: = Breast cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Clinical Outcome
3 results:
1. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
2. Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells.
Fan TC; Yeo HL; Hsu HM; Yu JC; Ho MY; Lin WD; Chang NC; Yu J; Yu AL
Cancer Lett; 2018 Oct; 434():184-195. PubMed ID: 30040982
[TBL] [Abstract] [Full Text] [Related]
3. Current Advances in Thyroid cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
Rusinek D; Chmielik E; Krajewska J; Jarzab M; Oczko-Wojciechowska M; Czarniecka A; Jarzab B
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829399
[TBL] [Abstract] [Full Text] [Related]
